Sanja Jelača
Research Assistant
Sanja Jelača
Sanja Jelača completed her undergraduate studies at the Faculty of Biology, University of Belgrade in 2016 and obtained a degree in biology. In 2016, she enrolled a Master's studies in Human Molecular Biology module at the Faculty of Biology, University of Belgrade. In 2017, she defended her Master's thesis entitled "Glucocorticoid signalling pathway in the liver of rats treated with 5α-dihydrotestosterone as an animal model of polycystic ovary syndrome." The experimental part of master's thesis was carried out at Biochemistry Department, IBISS. She enrolled a doctoral studies at the Faculty of Biology, University of Belgrade in 2018, on Molecular Oncology module. In October 2018, she obtained a title Junior Research Assistant, and since January 2019 she has been employed at Department of Immunology, IBISS. In September 2021, she obtained a title of Research Assistant. As a participant of two bilateral DAAD projects (2018-2021), she spent two months at the Leibniz Institute of Plant Biochemistry (IPB), Martin Luther University, Halle (Saale), Germany and one month at the Saxon Incubator for Clinical Translation (SIKT), Leipzig University, Leipzig, Germany. She was also a participant in one national project (2019), one bilateral project with China (2018-2021) and two projects with industry (2020-2022). She participates in the project of Science Fund of the Republic of Serbia from the Prisma programme (ADVANCED). She is an active member of Serbian biochemical society, European Federation of Biochemical Societies, The Serbian Society for Molecular Biology, Immunological Society of Serbia, European Federation of Immunological Societies, Serbian Association for Cancer Research, The European Association for Cancer Research, Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine, Club of Serbian Young Immunologist and Young European Federation of Immunological Societies. Her research interests are cancer biology, tumor immunology and experimental therapeutics.